Cacti Asset Management LLC Has $46.86 Million Holdings in CVS Health Corp (CVS)

Cacti Asset Management LLC grew its holdings in CVS Health Corp (NYSE:CVS) by 19.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 576,253 shares of the pharmacy operator’s stock after purchasing an additional 92,005 shares during the quarter. CVS Health comprises about 4.0% of Cacti Asset Management LLC’s investment portfolio, making the stock its 8th largest position. Cacti Asset Management LLC owned 0.06% of CVS Health worth $46,861,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CVS. Fieldpoint Private Securities LLC boosted its stake in CVS Health by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new position in CVS Health in the second quarter worth $119,000. Gemmer Asset Management LLC boosted its stake in CVS Health by 15.3% in the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares in the last quarter. Captrust Financial Advisors acquired a new position in CVS Health in the second quarter worth $155,000. Finally, Grace & White Inc. NY acquired a new position in CVS Health in the second quarter worth $199,000. 82.24% of the stock is currently owned by institutional investors.

In other CVS Health news, EVP Thomas M. Moriarty sold 20,547 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the transaction, the executive vice president now owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jonathan C. Roberts sold 85,743 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $83.14, for a total value of $7,128,673.02. Following the completion of the transaction, the chief operating officer now directly owns 119,555 shares in the company, valued at approximately $9,939,802.70. The disclosure for this sale can be found here. Corporate insiders own 0.61% of the company’s stock.

CVS Health Corp (NYSE:CVS) opened at $73.08 on Friday. CVS Health Corp has a one year low of $66.45 and a one year high of $84.72. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $71,719.84, a PE ratio of 12.40, a price-to-earnings-growth ratio of 1.33 and a beta of 0.89.

CVS Health (NYSE:CVS) last released its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same quarter in the prior year, the firm posted $1.64 earnings per share. The company’s quarterly revenue was up 3.5% on a year-over-year basis. equities research analysts expect that CVS Health Corp will post 5.9 EPS for the current fiscal year.

CVS has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of CVS Health in a research note on Sunday, September 10th. Oppenheimer reaffirmed a “buy” rating and set a $95.00 price target on shares of CVS Health in a research note on Monday, October 9th. Leerink Swann reaffirmed an “outperform” rating and set a $85.00 price target (down previously from $90.00) on shares of CVS Health in a research note on Tuesday, November 7th. BidaskClub lowered CVS Health from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Finally, SunTrust Banks set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the company. CVS Health presently has a consensus rating of “Buy” and a consensus target price of $86.35.

TRADEMARK VIOLATION WARNING: This report was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/16/cacti-asset-management-llc-has-46-86-million-holdings-in-cvs-health-corp-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply